ZYDUSLIFE.NS Profit & Loss
Zydus Lifesciences Ltd.
Profit & Loss Balance Sheet Cash Flow
Profit & Loss · 7 years on file
(FY2019-20 to FY2025-26)
· fetched 2026-08-24 01:31
| Line item | FY2019-20 | FY2020-21 | FY2021-22 | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹14,253.10 Cr. | ₹15,102.20 Cr. | ₹15,265.20 Cr. | ₹17,237.40 Cr. | ₹19,547.40 Cr. | ₹23,241.50 Cr. | ₹27,148.40 Cr. | RevenueFromOperations |
| Gross Revenue (incl. inter-segment) | ₹14,253.10 Cr. | ₹15,102.20 Cr. | ₹15,265.20 Cr. | ₹17,237.40 Cr. | ₹19,547.40 Cr. | ₹23,241.50 Cr. | ₹27,148.40 Cr. | SegmentRevenueFromOperations |
| Other Income | ₹113.90 Cr. | ₹37.20 Cr. | ₹224.70 Cr. | ₹186.60 Cr. | ₹284.10 Cr. | ₹269.50 Cr. | ₹509.50 Cr. | OtherIncome |
| Total Income | ₹14,367.00 Cr. | ₹15,139.40 Cr. | ₹15,489.90 Cr. | ₹17,424.00 Cr. | ₹19,831.50 Cr. | ₹23,511.00 Cr. | ₹27,657.90 Cr. | Income |
| Cost of Materials Consumed | ₹3,459.60 Cr. | ₹3,888.20 Cr. | ₹4,042.90 Cr. | ₹4,122.60 Cr. | ₹4,580.50 Cr. | ₹4,372.90 Cr. | ₹5,109.60 Cr. | CostOfMaterialsConsumed |
| Purchases of Stock-in-Trade | ₹1,554.20 Cr. | ₹1,471.10 Cr. | ₹1,864.60 Cr. | ₹1,949.40 Cr. | ₹1,897.90 Cr. | ₹2,150.00 Cr. | ₹3,070.50 Cr. | PurchasesOfStockInTrade |
| Changes in Inventories | ₹-93.80 Cr. | ₹-149.20 Cr. | ₹-362.30 Cr. | ₹238.10 Cr. | ₹-250.20 Cr. | ₹-184.90 Cr. | ₹-887.50 Cr. | ChangesInInventoriesOfFinishedGoodsWorkInProgressAndStockInTrade |
| Employee Benefit Expense | ₹2,414.50 Cr. | ₹2,490.20 Cr. | ₹2,434.10 Cr. | ₹2,765.60 Cr. | ₹3,137.60 Cr. | ₹3,680.60 Cr. | ₹4,417.90 Cr. | EmployeeBenefitExpense |
| Finance Costs | ₹341.80 Cr. | ₹163.50 Cr. | ₹127.00 Cr. | ₹129.90 Cr. | ₹81.20 Cr. | ₹165.90 Cr. | ₹438.90 Cr. | FinanceCosts |
| Depreciation and Amortisation | ₹696.50 Cr. | ₹724.80 Cr. | ₹713.00 Cr. | ₹722.70 Cr. | ₹764.10 Cr. | ₹915.80 Cr. | ₹1,408.00 Cr. | DepreciationDepletionAndAmortisationExpense |
| Other Expenses | ₹4,135.20 Cr. | ₹4,060.90 Cr. | ₹3,945.20 Cr. | ₹4,301.80 Cr. | ₹4,797.30 Cr. | ₹6,164.40 Cr. | ₹6,962.80 Cr. | OtherExpenses |
| Total Expenses | ₹12,508.00 Cr. | ₹12,649.50 Cr. | ₹12,764.50 Cr. | ₹14,230.10 Cr. | ₹15,008.40 Cr. | ₹17,264.70 Cr. | ₹20,520.20 Cr. | Expenses |
| Profit Before Exceptional Items and Tax | ₹1,859.00 Cr. | ₹2,489.90 Cr. | ₹2,725.40 Cr. | ₹3,193.90 Cr. | ₹4,823.10 Cr. | ₹6,246.30 Cr. | ₹7,137.70 Cr. | ProfitBeforeExceptionalItemsAndTax |
| Exceptional Items | ₹-363.60 Cr. | ₹-205.10 Cr. | ₹112.70 Cr. | ₹-604.20 Cr. | ₹-14.20 Cr. | ₹-219.60 Cr. | ₹-516.60 Cr. | ExceptionalItemsBeforeTax |
| Profit Before Tax | ₹1,495.40 Cr. | ₹2,284.80 Cr. | ₹2,838.10 Cr. | ₹2,589.70 Cr. | ₹4,808.90 Cr. | ₹6,026.70 Cr. | ₹6,621.10 Cr. | ProfitBeforeTax |
| Tax Expense | ₹319.80 Cr. | ₹147.20 Cr. | ₹511.70 Cr. | ₹587.80 Cr. | ₹977.50 Cr. | ₹1,411.90 Cr. | ₹1,594.70 Cr. | TaxExpense |
| Net Profit (incl. minority interest) | ₹1,204.40 Cr. | ₹2,185.00 Cr. | ₹4,618.30 Cr. | ₹2,091.90 Cr. | ₹3,972.80 Cr. | ₹4,672.60 Cr. | ₹5,123.50 Cr. | ProfitLossForPeriod |
| Net Profit (to shareholders) | ₹1,176.60 Cr. | ₹2,133.60 Cr. | ₹4,487.30 Cr. | ₹1,960.30 Cr. | ₹113.30 Cr. | ₹147.10 Cr. | ₹5,040.00 Cr. | ProfitOrLossAttributableToOwnersOfParent |
| Basic EPS | ₹11.49 | ₹20.84 | ₹43.84 | ₹19.30 | ₹38.14 | ₹44.97 | ₹50.09 | BasicEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
| Diluted EPS | ₹11.49 | ₹20.84 | ₹43.84 | ₹19.30 | ₹38.14 | ₹44.97 | ₹50.09 | DilutedEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
Every figure above is the exact value of the named XBRL element from ZYDUSLIFE.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).